Effective treatment of chronic lymphocytic leukemia: A Synthesis of Findings from 39 Studies

  1. Home
  2. Effective treatment of chronic lymphocytic leukemia
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of chronic lymphocytic leukemia: A Synthesis of Findings from 39 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of chronic lymphocytic leukemia: A Synthesis of Findings from 39 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that typically affects older adults. Traditional cytotoxic therapies for CLL have limited benefits in elderly patients and do not improve survival. 36 . However, with a better understanding of CLL biology, the trend is shifting towards the use of targeted therapies. 36 . Targeted therapies specifically target dysregulated pathways in CLL cells, aiming to reduce side effects while effectively treating the disease.

Ibrutinib is a targeted therapy that inhibits the B-cell receptor (BCR) signaling pathway, which is crucial for the growth of CLL cells. 36 . Combining ibrutinib with rituximab is expected to enhance its effectiveness. 34 . Research suggests that this combination therapy shows better efficacy than standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. 34 . However, the data regarding the effectiveness of the ibrutinib-rituximab combination is still limited. 34 .

Cladribine inhibits deoxycytidine kinase, thereby preventing DNA synthesis in CLL cells. 19 . Studies comparing cladribine monotherapy to combinations with cyclophosphamide or cyclophosphamide plus mitoxantrone found that the combination of cyclophosphamide and mitoxantrone achieved higher complete remission rates and better minimal residual disease (MRD) suppression. 19 . However, the combination therapy comes with higher risks of side effects compared to monotherapy. 19 .

Venetoclax is a Bcl-2 inhibitor that induces apoptosis in CLL cells. 37 . Combining venetoclax with obinutuzumab significantly reduces MRD, suggesting potential for long-term remission. 37 .

Lenalidomide is an immunomodulatory drug that inhibits the growth of CLL cells. 30 . As an add-on therapy after chemotherapy, lenalidomide may prolong progression-free survival. 32 . However, lenalidomide is known to have significant side effects. 30 .

These research findings indicate that, in addition to traditional chemotherapy, targeted therapies are effective for treating CLL. 36 . Targeted therapies can effectively inhibit CLL cell growth while minimizing side effects. 36 . However, targeted therapies are still under development and require further research.

treatment Summary

Ibrutinib inhibits the BCR signaling pathway, which is crucial for the growth of CLL cells. 36 . Combining ibrutinib with rituximab is expected to enhance its effectiveness. 34 . Cladribine inhibits deoxycytidine kinase, thereby preventing DNA synthesis in CLL cells. 19 . Studies comparing cladribine monotherapy to combinations with cyclophosphamide or cyclophosphamide plus mitoxantrone were conducted. 19 . Venetoclax is a Bcl-2 inhibitor that induces apoptosis in CLL cells. 37 . Combining venetoclax with obinutuzumab significantly reduces MRD, suggesting potential for long-term remission. 37 . Lenalidomide is an immunomodulatory drug that inhibits the growth of CLL cells. 30 . As an add-on therapy after chemotherapy, lenalidomide may prolong progression-free survival. 32 .

Benefits and Risks

Benefit Summary

In addition to traditional chemotherapy, targeted therapies are effective for treating CLL. 36 . Targeted therapies can effectively inhibit CLL cell growth while minimizing side effects. 36 . The ibrutinib-rituximab combination therapy shows better efficacy than standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. 34 . The combination therapy of cladribine with cyclophosphamide plus mitoxantrone showed higher complete remission rates and better minimal residual disease (MRD) suppression. 19 . Combining venetoclax with obinutuzumab significantly reduces MRD, suggesting potential for long-term remission. 37 . Lenalidomide may prolong progression-free survival when used as an add-on therapy after chemotherapy. 32 .

Risk Summary

The combination therapy of cladribine with cyclophosphamide plus mitoxantrone is known to have higher risks of side effects compared to monotherapy. 19 . Lenalidomide is known to have significant side effects. 30 .

Comparison between Studies

Commonalities

Many studies suggest that targeted therapies are effective for treating CLL, alongside traditional chemotherapy. 36 . Targeted therapies can effectively inhibit CLL cell growth while minimizing side effects. 36 .

Differences

Direct comparisons are difficult as each study utilizes different treatment approaches and evaluation criteria. For example, research on the effectiveness of the ibrutinib-rituximab combination is still limited. 34 . Moreover, concerns regarding the risk of side effects arise from studies exploring the combination of cladribine with cyclophosphamide and mitoxantrone. 19 .

Consistency and Contradictions in Results

Numerous studies demonstrate the effectiveness of targeted therapies in treating CLL, alongside traditional chemotherapy. 36 . However, direct comparisons are difficult due to the diverse treatment approaches and evaluation criteria employed in each study.

Considerations for Real-World Application

Choosing the optimal treatment approach for CLL requires considering factors such as the patient's age, overall health, stage of disease, and genetic information. 36 . Targeted therapies hold promise as less-invasive and effective treatment options, but they may not be suitable for all patients. 36 . It's crucial to consult a physician before starting any treatment.

Limitations of Current Research

CLL treatment options are constantly evolving. New therapies are being developed, raising hope for even more effective and safer treatments in the future. However, targeted therapies are still under development, and further research is needed to understand their long-term effects and side effects.

Future Research Directions

The following research areas are critical for further improving CLL treatment:

  • Developing novel targeted therapies
  • Conducting research on the long-term effects and side effects of targeted therapies
  • Developing personalized treatment strategies based on CLL genetic information

Conclusion

In addition to traditional chemotherapy, targeted therapies have shown effectiveness in treating CLL. 36 . Targeted therapies can effectively inhibit CLL cell growth while minimizing side effects. 36 . However, targeted therapies are still under development and require further research. Choosing the optimal treatment approach for CLL requires considering factors such as the patient's age, overall health, stage of disease, and genetic information. 36 . It's crucial to consult a physician before starting any treatment.

List of Treatments

Ibrutinib, Rituximab, Fludarabine, Cyclophosphamide, Cladribine, Mitoxantrone, Venetoclax, Obinutuzumab, Lenalidomide, Chlorambucil, Prednisone, Vincristine, Doxorubicin, Ofatumumab, Lenalidomide, Alemtuzumab, Bendamustine.

Keywords
Benefit Keywords
Complete remission
Longer survival
Minimal toxicity
1
Good remission rate
Improved survival
2
Complete remission with CHOP regimen
Improved survival with CHOP regimen
3
CLL response
Improved survival
6
Improved remission rates
7
Improved survival
9
Effective treatment
10
Improved response rates
11
Better response
Lower progression rate
12
chronic lymphocytic leukemia treatment
13
Improved CLL treatment
16
Longer progression-free survival
Longer remission
Treat CLL
17
B-CLL treatment
18
Higher CR rate
MRD suppression
19
Treatment of chronic lymphocytic leukemia
20
Improved CLL treatment
21
Improved PFS
Similar OS
23
CLL treatment
24
CLL progression prevention
OS increase
25
Improved survival
Increased remission
26
CLL treatment
27
CLL treatment efficacy
28
Adverse reaction reduction
CLL treatment
Symptom improvement
29
FCR chemoimmunotherapy
31
Improved CLL treatment
32
CLL treatment
Maintenance approaches
33
CLL survival improvement
Progression-free survival
34
CLL treatment
35
CLL treatment
Clinical outcomes
36
CLL treatment
37
Treatment for chronic lymphocytic leukemia
39
Risk Keywords
Diabetes mellitus
1
Modest toxicity
2
Increased epithelial cancers with chlorambucil
No improvement in survival with COP regimen
3
Chlorambucil side effects
4
COP ineffective
5
No survival advantage
8
chronic lymphocytic leukemia
13
Disease progression
15
Infection
Neutropenia
17
Infection
Neutropenia
Thrombocytopenia
18
Infections
Neutropenia
19
Immune thrombocytopenia
22
Late adverse events
23
Increased adverse reactions
Increased neutropenia
26
Prolonged neutropenia
Secondary malignancy
28
Toxicity
30
CLL
31
SPM following CIT for CLL
38
Literature analysis of 39 papers
Positive Content
31
Neutral Content
4
Negative Content
4
Article Type
28
8
6
6
39
1.

Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.

Author: SawitskyA, RaiK R, GlidewellO, SilverR T

Complete remission
Longer survival
Minimal toxicity
Diabetes mellitus

A study of 96 patients with stage III and stage IV chronic lymphocytic leukemia found that prednisone plus chlorambucil was more effective than prednisone alone, but there was no significant difference in overall survival between the three treatment schedules.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

2.

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.

Author: RaphaelB, AndersenJ W, SilberR, OkenM, MooreD, BennettJ, BonnerH, HahnR, KnospeW H, MazzaJ

Good remission rate
Improved survival
Modest toxicity

A study comparing two chemotherapy regimens for advanced chronic lymphocytic leukemia found no significant difference in survival, remission rates, or duration of response. The results suggest that intermittent chlorambucil plus prednisone remains the standard treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

3.

The experience of the French Cooperative Group in the treatment of CLL.

Author: TravadeP

Complete remission with CHOP regimen
Improved survival with CHOP regimen
Increased epithelial cancers with chlorambucil
No improvement in survival with COP regimen

This study compared different treatment approaches for chronic lymphocytic leukemia (CLL) based on disease stage. For early-stage CLL, no treatment was found to be more effective than observation, and chemotherapy (chlorambucil) was associated with a higher risk of other cancers. For intermediate-stage CLL, there was no improvement in survival with a more intensive chemotherapy regimen (COP) compared to chlorambucil alone. For advanced-stage CLL, a more intensive chemotherapy regimen (CHOP) was confirmed to be effective. In a separate study, CHOP treatment was more effective than chlorambucil-prednisone for intermediate-stage CLL, but longer follow-up is needed to assess survival benefits. Overall, the study suggests that treatment for CLL needs to be tailored to the stage of the disease.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia.

Author:

Chlorambucil side effects

A study of 612 patients with chronic lymphocytic leukemia found that untreated patients with good prognosis (stage A) had better overall survival compared to those treated with chlorambucil, although the difference was not statistically significant. Chlorambucil slowed down disease progression but was associated with shorter survival after disease progression. The study suggests that patients with stage A, hemoglobin levels greater than or equal to 120 g/L, and a lymphocyte count less than 30 x 10(9)/L may not require treatment unless disease progression is observed.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia.

Author:

COP ineffective

This study compared the effectiveness of chlorambucil and a more intensive chemotherapy regimen (COP) in 291 patients with intermediate-stage chronic lymphocytic leukemia (CLL). After a mean follow-up of 53 months, there was no significant difference in overall survival between the two groups. The study found similar survival rates, remission rates, time to disease progression, and causes of death between the groups. This suggests that a more intensive chemotherapy regimen does not improve outcomes for intermediate-stage CLL compared to chlorambucil treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C.

Author: MontserratE, AlcaláA, AlonsoC, BesalduchJ, MoraledaJ M, García-CondeJ, GutierrezM, GomisF, GarijoJ, GuzmánM C

CLL response
Improved survival

This study compared two chemotherapy regimens for 96 patients with chronic lymphocytic leukemia (CLL): chlorambucil plus prednisone (CLR + PDN) and cyclophosphamide, melphalan, and prednisone (CMP). CLR + PDN resulted in a higher response rate (75%) compared to CMP (54.5%). While more patients in stage B CLL responded to treatment compared to those with stage C, this difference was not statistically significant. There was no significant difference in survival between the two treatment groups. The study concludes that both regimens are effective for CLL, with CLR + PDN having a slightly higher response rate.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Therapy of chronic lymphocytic leukemia patients. Results from the French cooperative trials. French Cooperative Group on Chronic Lymphocytic Leukemia.

Author:

Improved remission rates

A review of clinical trials for chronic lymphocytic leukemia found that CHOP chemotherapy was more effective than COP in stage C patients and intermittent chlorambucil-prednisone in stage B patients. Daily indefinite chlorambucil was associated with a negative impact on survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation.

Author: ShustikC, MickR, SilverR, SawitskyA, RaiK, ShapiroL

No survival advantage

This study compared the effectiveness of early treatment with chlorambucil to no treatment for 59 patients with early-stage chronic lymphocytic leukemia (CLL). After 5 years, there was no significant difference in survival between the groups. However, a higher percentage of patients in the untreated group (70%) were experiencing active disease compared to the treated group (55%). The study concludes that early treatment with chlorambucil does not improve survival for patients with early-stage CLL.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial.

Author: KellerJ W, KnospeW H, RaneyM, HuguleyC M, JohnsonL, BartolucciA A, OmuraG A

Improved survival

A study of 178 patients with chronic lymphocytic leukemia found that intermittent chlorambucil and prednisone treatment was effective, but adding cyclophosphamide and cytosine arabinoside did not improve outcomes.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

10.

A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases.

Author: JacobsP, KingH S

Effective treatment

A study of 108 patients with indolent lymphoproliferative diseases compared chlorambucil and prednisone (CP) chemotherapy to fractionated total body irradiation (TBI). Both treatments had similar complete remission rates (CR) and survival times. For the entire group, the CR rates were 59% for CP and 52% for TBI, with median survivals of 53 and 57 months, respectively. Similar results were observed within subgroups of chronic lymphocytic leukemia (CLL), well-differentiated lymphocytic lymphoma (WDLL), and follicular lymphoma (FL). These findings suggest that CP and TBI are equally effective initial treatment options for indolent lymphoproliferative diseases, regardless of the specific disease type.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.

Author: MontserratE, AlcaláA, ParodyR, DomingoA, García-CondeJ, BuenoJ, FerránC, SanzM A, GiraltM, RubioD

Improved response rates

A study of 96 patients with advanced chronic lymphocytic leukemia (CLL) compared two chemotherapy regimens: chlorambucil plus prednisone (CLR+PDN) and cyclophosphamide, vincristine, and prednisone (COP). CLR+PDN resulted in a higher response rate (59%) compared to COP (31%), but survival was similar between the groups. Patients who had received prior treatment had lower response rates compared to those who had not received prior treatment. Patients achieving complete or good partial remission had longer survival compared to those with poor remission or no response. These findings suggest that CLR+PDN may be a more effective initial treatment for CLL, but further research is needed to optimize treatment strategies based on individual patient factors.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

12.

Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial.

Author: BrugiatelliM, JaksicB, Planinc-PeraicaA, KusecR, OstojicS, CalleaV, IacopinoP, MorabitoF, StelitanoC, LutzD

Better response
Lower progression rate

This study compared immediate treatment with chlorambucil (CLB) versus delaying treatment until disease progression in 148 patients with early, stable chronic lymphocytic leukemia (CLL). After a median follow-up of 75 months, there was no significant difference in overall survival between the two groups. While early treatment resulted in better initial response and a slower progression of the disease, it did not improve survival. This study suggests that immediate chemotherapy with CLB is not beneficial for patients with early, stable CLL in terms of survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia.

Author:

chronic lymphocytic leukemia treatment
chronic lymphocytic leukemia

This study of 287 stage B and 90 stage C chronic lymphocytic leukemia (CLL) patients found that while CHOP regimen improved treatment response in stage B patients, it did not improve survival compared to chlorambucil plus prednisone. In stage C, no significant difference was found between CHOP and CHOP plus methotrexate in terms of treatment response or survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.

Author: JaksicB, BrugiatelliM, KrcI, LosoncziH, HolowieckiJ, Planinc-PeraicaA, KusecR, MorabitoF, IacopinoP, LutzD

This study is investigating the effectiveness of two chemotherapy regimens for advanced chronic lymphocytic leukemia (CLL): a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus continuous high-dose chlorambucil (HD-CLB). The study aims to determine which regimen is more effective for patients with this type of leukemia.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

15.

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Author: DighieroG, MaloumK, DesablensB, CazinB, NavarroM, LeblayR, LeporrierM, JaubertJ, LepeuG, DreyfusB, BinetJ L, TravadeP

Disease progression

Two randomized trials found that chlorambucil treatment did not increase survival in patients with indolent chronic lymphocytic leukemia (CLL). The studies suggest that treatment of indolent CLL is unnecessary and that deferring therapy until the disease progresses does not compromise survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

16.

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.

Author:

Improved CLL treatment

This study examined the impact of different chemotherapy approaches on survival in patients with chronic lymphocytic leukemia (CLL). The researchers compared the following: * Immediate versus delayed chemotherapy for early-stage CLL. * Combination chemotherapy (e.g., COP or CHOP) versus single-agent chlorambucil for more advanced CLL. The study was conducted because previous trials were too small to provide reliable results on these specific comparisons.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Author: RaiK R, PetersonB L, AppelbaumF R, KolitzJ, EliasL, ShepherdL, HinesJ, ThreatteG A, LarsonR A, ChesonB D, SchifferC A

Longer progression-free survival
Longer remission
Treat CLL
Infection
Neutropenia

This study found that fludarabine yielded higher response rates and a longer duration of remission and progression-free survival than chlorambucil in patients with chronic lymphocytic leukemia.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

18.

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

Author: RobakT, BłońskiJ Z, KasznickiM, Góra-TyborI, Dwilewicz-TrojaczekJ, BoguradzkiP, KonopkaL, CeglarekB, SułekJ, KuliczkowskiK, WołowiecD, Stella-HołowieckaB, SkotnickiA B, NowakW, Moskwa-SrokaB, DmoszyńskaA, CalbeckaM

B-CLL treatment
Infection
Neutropenia
Thrombocytopenia

This study evaluated the effectiveness and toxicity of a combined chemotherapy regimen (CMC) consisting of cladribine, mitoxantrone, and cyclophosphamide in treating previously untreated B-cell chronic lymphocytic leukemia (B-CLL). The study found that CMC achieved an overall response rate of 64.5%, with 29% of patients achieving complete remission. While the regimen was effective, it also resulted in significant toxicity, particularly with the CMC5 protocol. The authors recommend further investigation of the CMC3 regimen for treating B-CLL patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).

Author: RobakTadeusz, BlonskiJerzy Z, Gora-TyborJoanna, JamroziakKrzysztof, Dwilewicz-TrojaczekJadwiga, TomaszewskaAgnieszka, KonopkaLech, CeglarekBernadetta, DmoszynskaAnna, KowalMalgorzata, KloczkoJanusz, Stella-HolowieckaBeata, SulekKazimierz, CalbeckaMalgorzata, ZawilskaKrystyna, KuliczkowskiKazimierz, SkotnickiAleksander B, WarzochaKrzysztof, KasznickiMarek,

Higher CR rate
MRD suppression
Infections
Neutropenia

This prospective randomized trial compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in treating untreated progressive chronic lymphocytic leukemia (CLL).

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

Author: WierdaWilliam G, O'BrienSusan, WangXuemei, FaderlStefan, FerrajoliAlessandra, DoKim-Anh, Garcia-ManeroGuillermo, CortesJorge, ThomasDeborah, KollerCharles A, BurgerJan A, LernerSusan, SchletteEllen, AbruzzoLynne, KantarjianHagop M, KeatingMichael J

Treatment of chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) affects people differently, with some experiencing a slow progression that doesn't require treatment, while others have a more aggressive form that needs early intervention. This study identifies factors that predict when people with CLL will need treatment by analyzing the factors associated with time until treatment initiation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.

Author: ChengMindy M, GoulartBernardo, VeenstraDavid L, BloughDavid K, DevineEmily Beth

Improved CLL treatment

This study notes that there are multiple treatment options for patients with chronic lymphocytic leukemia (CLL) who have not yet received treatment. While these treatments have been compared to chlorambucil, a common medication, there is no single standard treatment agreed upon by medical experts.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

22.

Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.

Author: BlonskiJerzy Z, RobakTadeusz, ChojnowskiKrzysztof, Gora-TyborJoanna, WarzochaKrzysztof, CeglarekBernadetta, SeferynskaIlona, CalbeckaMalgorzata, KostyraAleksandra, Stella-HolowieckaBeata, KloczkoJanusz, DmoszynskaAnna, KowalMalgorzata, LewandowskiKrzysztof, Dwilewicz-TrojaczekJadwiga, WiaterElzbieta, KuliczkowskiKazimierz, PotoczekStanislaw, HellmannAndrzej, MitalAndrzej, SkotnickiAleksander, NowakWieslaw, SulekKazimierz, ZawilskaKrystyna, TrelinskiJacek

Immune thrombocytopenia

Immune thrombocytopenia occurred in 7.1% of patients with chronic lymphocytic leukemia (CLL) treated with cladribine or chlorambucil. While the frequency of immune thrombocytopenia was similar between the two groups, the severity of bleeding was more pronounced in the cladribine group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.

Author: RobakTadeusz, BlonskiJerzy Z, Gora-TyborJoanna, CalbeckaMalgorzata, Dwilewicz-TrojaczekJadwiga, BoguradzkiPiotr, DmoszynskaAnna, KowalMalgorzata, KloczkoJanusz, PiszczJaroslaw, Stella-HolowieckaBeata, SulekKazimierz, KuliczkowskiKazimierz, PotoczekStanislaw, WarzochaKrzysztof, Lech-MarandaEwa, SkotnickiAleksander B, PiotrowskaMagdalena, MoskwaAndrzej, ZawilskaKrystyna, JamroziakKrzysztof

Improved PFS
Similar OS
Late adverse events

This study analyzed the long-term outcomes of different treatment regimens for chronic lymphocytic leukemia (CLL) over a 10-year period. The results showed that cladribine-based combinations extended progression-free survival compared to cladribine monotherapy, but overall survival was similar. Late adverse events, including infections, autoimmune complications, and secondary neoplasms, were comparable across the treatment groups.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.

Author: ŻołnierczykJolanta D, BorowiakArleta, BłońskiJerzy Z, Cebula-ObrzutBarbara, RogalińskaMałgorzata, KotkowskaAleksandra, WawrzyniakEwa, SmolewskiPiotr, RobakTadeusz, KiliańskaZofia M

CLL treatment

Chronic lymphocytic leukemia (CLL) is a type of cancer with varied characteristics due to differences in how cells regulate their life cycle and death. A key goal of CLL treatment is to overcome resistance to cell death and trigger this process in cancerous cells.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.

Author: LadyzynskiPiotr, MolikMaria, FoltynskiPiotr

CLL progression prevention
OS increase

This study compared the clinical effectiveness of available therapies for treatment-naïve, symptomatic chronic lymphocytic leukemia. The study found that in younger/fit patients, fludarabine with cyclophosphamide and rituximab (FCR) had the highest potential to prevent CLL progression. In older/unfit patients, chlorambucil with obinutuzumab (GClb) demonstrated the longest projected progression-free survival and had the highest potential for increasing overall survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.

Author: NunesAltacílio Aparecido, da SilvaAnderson Soares, SouzaKathiaja Miranda, KouryChristine de Nazaré Silva, de MelloLuane Marques

Improved survival
Increased remission
Increased adverse reactions
Increased neutropenia

Fludarabine plus cyclophosphamide (FC) with rituximab (FCR) showed better results in terms of complete remission, progression-free survival, and overall survival than FC alone in patients with chronic lymphocytic leukemia (CLL). However, FCR also showed a higher rate of neutropenia and serious adverse reactions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

27.

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Author: CramerPaula, IsfortSusanne, BahloJasmin, StilgenbauerStephan, DöhnerHartmut, BergmannManuela, StauchMartina, KnebaMichael, LangeElisabeth, LangerbeinsPetra, PflugNatali, KovacsGabor, GoedeValentin, FinkAnna-Maria, ElterThomas, FischerKirsten, WendtnerClemens-Martin, HallekMichael, EichhorstBarbara

CLL treatment

This study analyzed the outcomes of 1,558 patients with chronic lymphocytic leukemia (CLL) and found that treatments combining chemotherapy and antibody medications were more effective than chemotherapy alone. While many patients with early relapse received aggressive combination therapies, there was no benefit compared to less intensive treatments. The analysis confirmed that chemoimmunotherapy is the most effective treatment for CLL.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

28.

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Author: FischerKirsten, BahloJasmin, FinkAnna Maria, GoedeValentin, HerlingCarmen Diana, CramerPaula, LangerbeinsPetra, von TresckowJulia, EngelkeAnja, MaurerChristian, KovacsGabor, HerlingMarco, TauschEugen, KreuzerKarl-Anton, EichhorstBarbara, BöttcherSebastian, SeymourJohn F, GhiaPaolo, MarltonPaula, KnebaMichael, WendtnerClemens-Martin, DöhnerHartmut, StilgenbauerStephan, HallekMichael

CLL treatment efficacy
Prolonged neutropenia
Secondary malignancy

Chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for chronic lymphocytic leukemia (CLL). This long-term follow-up study examines the safety and efficacy of FC and FCR in treatment-naïve patients with CLL.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

29.

[Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].

Author: HanHui-Jie, LuYue-Wu, XiaRui-Xiang

Adverse reaction reduction
CLL treatment
Symptom improvement

Rituximab combined with fludarabine and cyclophosphamide showed a higher remission rate and effectively improved symptoms and reduced adverse reaction incidence compared to CHOP chemotherapy in patients with chronic lymphocytic leukemia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Chinese

30.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Author: KhouriMaria R, JabbourElias J, GulbisAlison M, TurturroFrancesco, LedesmaCelina, KorblingMartin, SamuelsBarry I, AhmedSairah, AlousiAmin M, CiureaStefan O, MarinDavid, PatelKrina K, PopatUday R, Bueso-RamosCarlos E, BassettRoland L, KhouriIssa F

Toxicity

This study examines the use of lenalidomide for treating persistent chronic lymphocytic leukemia (CLL) after allogeneic stem cell transplantation (alloSCT). The study found that lenalidomide was associated with high toxicity and did not improve survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

31.

FCR achieves long-term durable remissions in patients with <i>IGHV</i>-mutated CLL.

Author: Chai-AdisaksophaChatree, BrownJennifer R

FCR chemoimmunotherapy
CLL

This systematic review assesses the benefit of fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy for chronic lymphocytic leukemia (CLL) patients with mutated IGHV.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

32.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Author: ByrdJohn C, RuppertAmy S, HeeremaNyla A, HalvorsonAlese E, HokeEva, SmithMitchell R, GodwinJohn E, CoubanStephen, FehnigerTodd A, ThirmanMichael J, TallmanMartin S, AppelbaumFrederick R, StoneRichard M, RobinsonSue, ChangJulie E, MandrekarSumithra J, LarsonRichard A

Improved CLL treatment

This phase 2 study compared the effectiveness of three chemoimmunotherapy regimens (fludarabine plus rituximab [FR], FR plus lenalidomide consolidation [FR+L], and FR plus cyclophosphamide [FCR]) for untreated patients with non-del(11q) chronic lymphocytic leukemia (CLL), highlighting the potential for lenalidomide in improving outcomes.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

33.

Remission maintenance treatment options in chronic lymphocytic leukemia.

Author: EgleAlexander, PleyerLisa, MelchardtThomas, HartmannTanja Nicole, GreilRichard

CLL treatment
Maintenance approaches

Treatment for chronic lymphocytic leukemia (CLL) has improved significantly in recent years, with new medications extending survival and even eliminating detectable cancer in some patients. While most treatments are given for a limited period of time, newer medications that target specific pathways involved in cancer growth are being studied for long-term use. This review examines the results of recent research on long-term treatments, including maintenance therapy, to control CLL.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

34.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Author: ShanafeltTait D, WangXin V, KayNeil E, HansonCurtis A, O'BrienSusan, BarrientosJacqueline, JelinekDiane F, BraggioEsteban, LeisJose F, ZhangCong C, CoutreSteven E, BarrPaul M, CashenAmanda F, MatoAnthony R, SinghAvina K, MullaneMichael P, LittleRichard F, ErbaHarry, StoneRichard M, LitzowMark, TallmanMartin

CLL survival improvement
Progression-free survival

Ibrutinib-rituximab was superior to a standard chemoimmunotherapy regimen in patients with previously untreated chronic lymphocytic leukemia (CLL).

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

35.

A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.

Author: LeeCho-Hao, ChenPo-Huang, LinChin, WangChieh-Yung, HoChing-Liang

CLL treatment

Chronic lymphocytic leukemia (CLL) is a type of cancer that can't be cured with standard treatments. While initial treatments are often effective, most people eventually experience a return of the cancer within five years. Maintaining treatment with medications like lenalidomide, rituximab, or ofatumumab may help to keep the disease in remission for a longer period compared to not using these medications. However, more research is needed to compare the effectiveness and safety of these different maintenance therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

36.

Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.

Author: FarooquiArafat Ali, AshrafAqsa, FarooqTalha Bin, AnjumAhmad, RehmanSaif Ur, AkbarArshia, KanateAbraham, DeanRobert, AhmedMalik Qistas, TariqMuhammad Junaid, NabeelShaha, FaisalMuhammad Salman, AnwerFaiz

CLL treatment
Clinical outcomes

This review focuses on the safety and efficacy of novel targeted therapies for chronic lymphocytic leukemia (CLL), particularly in elderly patients. The review highlights the increasing use of agents targeting dysregulated pathways, such as BCR inhibitors, PI3K inhibitors, spleen tyrosine kinase inhibitors, Bcl-2 inhibitors, immunomodulators, and monoclonal antibodies, which have shown promising results with tolerable toxicity profiles in elderly patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

37.

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

Author: Al-SawafOthman, ZhangCan, LuTong, LiaoMichael Z, PanchalAnesh, RobrechtSandra, ChingTravers, TandonManeesh, FinkAnna-Maria, TauschEugen, SchneiderChristof, RitgenMatthias, BöttcherSebastian, KreuzerKarl-Anton, ChylaBrenda, MilesDale, WendtnerClemens-Martin, EichhorstBarbara, StilgenbauerStephan, JiangYanwen, HallekMichael, FischerKirsten

CLL treatment

Venetoclax and obinutuzumab (Ven-Obi) treatment for previously untreated chronic lymphocytic leukemia (CLL) resulted in high rates of minimal residual disease (MRD) negativity and long-term disease control.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

38.

Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review.

Author: CsanádiMarcell, ÁghTamás, TordaiAttila, TapprichChristoph, VokóZoltán, StamatopoulosKostas

SPM following CIT for CLL

This study analyzed clinical trial data on the occurrence of secondary primary malignancies (SPM) in treatment-naïve chronic lymphocytic leukemia (CLL) patients following chemo-immunotherapy (CIT). The study explores the potential link between therapy-related cytotoxicity, immunodeficiency, and the development of SPM in CLL patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

39.

Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.

Author: AlrawashdhNeda, McBrideAli, ErstadBrian, SweasyJoann, PerskyDaniel O, AbrahamIvo

Treatment for chronic lymphocytic leukemia

This study estimated the 10-year cost-effectiveness of various treatment regimens for chronic lymphocytic leukemia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.